Human review is essential for AI-ready preclinical data

Validation cannot resolve scientific ambiguity

A schema can tell you that a field is missing or that a unit is invalid. It cannot always decide whether an endpoint definition is fit for a context of use, whether an ontology term is biologically precise enough, or whether a protocol deviation changes interpretation. Those are expert judgements.

This is why human-in-the-loop curation is not a cosmetic approval button. It is part of the data quality system. The reviewer should see the extracted value, source evidence, model confidence, validation result, and reason the field was routed for review.

The right review points are predictable

Not every metadata field needs the same level of oversight. Stable fields such as date, file identifier, or instrument serial number can often be validated automatically. High-impact fields need human review: context of use, biological relevance rationale, endpoint interpretation, donor eligibility, protocol deviations, uncertainty statements, and regulatory claim linkage.

A good workflow routes effort where it matters. The agent extracts and validates; the system classifies risk; the human resolves ambiguity before the record becomes persistent evidence.

LangGraph-style workflows fit this pattern

Human-in-the-loop agent frameworks such as LangGraph support interrupts, checkpoints, and resume logic. That matters for curation because review is rarely instantaneous. A metadata workflow may need to pause, present an unresolved field to a scientist, record an edit or approval, and then continue without rerunning the entire extraction.

The same pattern can support quality gates before export: no evidence package should be released if required fields remain unresolved or if human-reviewed decisions are missing from the audit trail.

AI-ready means accountable, not fully automated

Bridge2AI-style AI-readiness includes provenance, characterization, computability, explainability, sustainability, and ethical documentation. Those criteria point toward accountable automation, not unchecked automation. The system should make it clear what was extracted by a model, what was validated by software, and what was approved by a human.

For preclinical data, this distinction is practical. The goal is not to make curation invisible. The goal is to make the data, the uncertainty, and the review decisions explicit enough that other humans and machines can reuse them responsibly.